{'fraction_non_alphanumeric': 0.026364477335800184, 'fraction_numerical': 0.0064754856614246065, 'mean_word_length': 5.110169491525424, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Abstract 17101: Targeting of Heparin-Binding EGF-Like Growth Factor (HB-EGF) Effectively Protected Against Hyperlipidemia-Associated Vascular and Hepatic Inflammations


 Introduction:
 Obesity and hepatic VLDL overproduction are key risk factors for the development of dyslipidemia and metabolic inflammatory diseases including atherosclerosis and non-alcoholic fatty liver disease (NAFLD). HB-EGF is a representative mediator for sustained EGFR transactivation under diverse oxidative stress environments including central obesity. A previous report showed that, in C57BL/6 mice, an injection of recombinant HB-EGF significantly increased apoB and TG secretion from the liver; in contrast, HB-EGF antisense oligonucleotide (ASO) administration induced a significant suppression of the hepatic VLDL secretion.
 
 
 Hypothesis:
 In this study, we tested the hypothesis, which was, that HB-EGF is an autonomous stimulator for the hepatic VLDL production in the liver, which would result in the development of hypertriglyceridemia, causing metabolic inflammatory diseases when under obese and over-nutrition.
 
 
 Methods and Results:
 In liver-derived cell line HepG2, recombinant HB-EGF treatment induced an autonomous increase of apoB production in the cells. In LDLR deficient mice under a western diet, which showed a list of metabolic syndrome phenotypes, HB-EGF ASO administration induced an effective downregulation of circulatory VLDL and TG level. The HB-EGF ASO administration also showed effective protection against atherosclerosis and non-alcoholic steatohepatitis (NASH) phenotypes in the mouse model.
 
 
 Conclusions:
 The results suggest that HB-EGF is a positive stimulator of hepatic VLDL production that may cause hypertriglyceridemia under obese and over-nutrition. It was also demonstrated that HB-EGF targeting could be an effective approach to prevent and reverse vascular and hepatic inflammations as shown in a mouse model.
 
 
 Figure:
 LDLR deficient mice under western diet were treated with control and HB-EGF ASOs for 12 weeks. CD68 positive cell content and inflammatory gene MCP1 transcription level in liver were compared.
 
 
 
